Investigation of a mechanism for Leydig cell tumorigenesis by linuron in rats.

Abstract

In a previously conducted 2-year study, a concentration-dependent increase in Leydig cell adenomas was observed in Crl:CD BR(CD) rats fed diets containing the herbicide linuron. Linuron has been shown to be negative in a battery of six tests for genotoxicity; therefore, a nongenotoxic mechanism of tumorgenesis was investigated. Linuron is structurally related to the nonsteroidal antiandrogen, flutamide. Flutamide has also been shown to produce Leydig cell tumors within 1 year, presumably due to sustained hypersecretion of luteinizing hormone (LH) which occurs following disruption of the hypothalamic-pituitary-testicular (HPT) axis. To investigate whether linuron possesses antiandrogenic activity, sexually immature and mature CD rats were administered either 200 mg/kg linuron or 10 mg/kg flutamide (positive control) for 2 weeks. Accessory sex organs were weighed and serum hormone levels were measured to assess androgen status and alterations in the HPT axis. Serum from a multigeneration reproduction study with linuron was also analyzed for serum hormone levels. In addition, competitive receptor binding studies were conducted to evaluate the ability of linuron to bind to the androgen receptor. Linuron decreased accessory sex organ weights in sexually immature and mature linuron-treated rats. Increased serum estradiol and LH levels were observed in sexually mature linuron-treated rats. Serum estradiol and LH levels were also elevated in P1 and F1 male rats from the multigeneration reproduction study. These accessory sex organ and hormonal changes are consistent with those seen with the antiandrogen flutamide, the only exception being serum testosterone, which was elevated following exposure to flutamide but not to linuron. The inability of linuron to increase testosterone levels may reflect the lower potency of linuron as an antiandrogen compared with that of flutamide, which is a potent antiandrogen. Additionally, linuron competed with [3H]testosterone for binding to the androgen receptor. The IC50 data for competition to the androgen receptor suggest that linuron is approximately 3.5 times less potent than flutamide. These data are consistent with the effects seen with flutamide and demonstrate that linuron is a less potent antiandrogen than flutamide. Collectively, these data support the hypothesis that linuron produces Leydig cell tumors via an antiandrogenic mechanism where sustained hypersecretion of LH appears to be responsible for the development of Leydig cell hyperplasia and adenomas.

• Authors: J C Cook, L S Mullin, S R Frame, L B Biegel
• Journal: Toxicology and applied pharmacology (Toxicol Appl Pharmacol) Vol. 119 Issue 2 Pg. 195-204 (Apr 1993) ISSN: 0041-008X [Print] United States
• PMID: 8480329 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Androgen Antagonists
• Receptors, Androgen
• Linuron
• Testosterone
• Estradiol
• Flutamide
• Luteinizing Hormone

Topics

• Age Factors
• Androgen Antagonists (metabolism, pharmacology)
• Animals
• Binding, Competitive
• Body Weight (drug effects)
• Cell Transformation, Neoplastic (chemically induced)
• Estradiol (blood)
• Female
• Flutamide (metabolism, pharmacology)
• Genitalia, Male (drug effects)
• In Vitro Techniques
• Leydig Cells (drug effects)
• Linuron (metabolism, pharmacology)
• Luteinizing Hormone (blood)
• Male
• Organ Size (drug effects)
• Pedigree
• Rats
• Rats, Inbred Strains
• Receptors, Androgen (drug effects)
• Testosterone (blood)